Clinical Trial Update: A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

View source ↗

Summary

This ClinicalTrials.gov entry describes a real-world study of trastuzumab deruxtecan (Enhertu) in Chinese patients with HER2-overexpressing and HER2-low advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: HER2 Overexpression, Advanced Stage Breast Cancer | Status: NOT_YET_RECRUITING